NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NGNE NEUROGENE INC

Market Closed 10-25 16:00:00 EDT

48.37

+0.17

+0.35%

盘后48.37

+0.000.00%

18:08 EDT

High50.85	Low47.76	Vol80.71K
Open48.45	D1 Closing48.20	Amplitude6.41%
Mkt Cap628.50M	Tradable Cap245.56M	Total Shares12.99M
T/O3.93M	T/O Rate1.59%	Tradable Shares5.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":48.37,"timestamp":1729886400000,"preClose":48.2,"halted":0,"volume":80711,"hourTrading":{"tag":"盘后","latestPrice":48.37,"preClose":48.37,"latestTime":"18:08 EDT","volume":258,"amount":12479.18,"timestamp":1729894128318},"delay":0,"floatShares":5076638,"shares":12993613,"eps":0.182564,"marketStatus":"Market Closed","change":0.17,"latestTime":"10-25 16:00:00 EDT","open":48.45,"high":50.85,"low":47.76,"amount":3929539.32994,"amplitude":0.064108,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.182564,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730102400000},"marketStatusCode":7,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":48.2,"postHourTrading":{"tag":"盘后","latestPrice":48.37,"preClose":48.37,"latestTime":"18:08 EDT","volume":258,"amount":12479.18,"timestamp":1729894128318},"volumeRatio":0.7101528856588704,"impliedVol":1.2088,"impliedVolPercentile":0.9423},"requestUrl":"/m/hq/s/NGNE","defaultTab":"news","newsList":[{"id":"2477260800","title":"Promising Therapeutic Potential of Neurogene’s NGN-401 in Treating Rett Syndrome Drives Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2477260800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477260800?lang=en_us&edition=fundamental","pubTime":"2024-10-22 17:15","pubTimestamp":1729588512,"startTime":"0","endTime":"0","summary":"Neurogene (NGNE) has received a new Buy rating, initiated by William Blair analyst, Sami Corwin. Sami Corwin’s rating is based on the promising the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-therapeutic-potential-of-neurogenes-ngn-401-in-treating-rett-syndrome-drives-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-therapeutic-potential-of-neurogenes-ngn-401-in-treating-rett-syndrome-drives-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2477985998","title":"Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2477985998","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477985998?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:30","pubTimestamp":1729510200,"startTime":"0","endTime":"0","summary":"Company to host webcast to review data on November 11 at 4:30 p.m. ET. Late-breaker poster to be presented during Child Neurology Society Meeting on November 12. NEW YORK, October 21, 2024----Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared.These data will also be presented in a late-breaking poster presentation during the 53rd Annual Child Neurology Society  Annual Meeting on November 12 at 12:30 p.m. PT in San Diego, CA.Neurogene’s Analyst and Investor Webcast/Conference Call","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rNb8rpGD7WhlPvgrajgGdQ--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2fdf96a2a9eecfe9a11e6088d9185b07","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rNb8rpGD7WhlPvgrajgGdQ--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2fdf96a2a9eecfe9a11e6088d9185b07"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-present-interim-clinical-data-113000741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CNS","NGNE","BK4135"],"gpt_icon":0},{"id":"2467770936","title":"BlackRock Health Sciences Term Trust Q2 2024 Commentary","url":"https://stock-news.laohu8.com/highlight/detail?id=2467770936","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467770936?lang=en_us&edition=fundamental","pubTime":"2024-09-13 22:30","pubTimestamp":1726237800,"startTime":"0","endTime":"0","summary":"The Trust underperformed its benchmark in Q2 2024, returning -4.4% on NAV and -4.0% on market price, compared to the benchmark's -2.9%.Strong earnings in the health care sector, particularly in GLP-1 ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/909708308/image_909708308.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/909708308/image_909708308.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4720989-blackrock-healthsciences-term-trust-q2-2024-commentary","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BLK","IE00BKVL7J92.USD","LU0154236417.USD","LU0354030438.USD","LU2430703178.SGD","LU0267386448.USD","ISRG","BK4505","03165","LU1934455194.USD","CABA","LU0772969993.USD","LU1280957306.USD","NVO","SARTF","AMGN","CRL","IE00B7SZLL34.SGD","LU0742537680.HKD","LU1023059063.AUD","LU1509826696.USD","LU2506951958.HKD","UTHR","LU2505996509.AUD","BSX","JNJ","LU1057294990.SGD","LU2506952097.USD","LU0114720955.EUR","LU0950375773.USD","BK4530","ALNY","MRUS","NGNE","LU2430703095.HKD","SILK","TSHA","LU1037948541.HKD","LU1974910355.USD","LU1917777945.USD","LU2491049909.HKD","RHHBY","MRK","IMCR","NAV","BMEZ","LU0320765489.SGD","LU0965509010.AUD","LU1267930813.SGD","LU1941712264.USD"],"gpt_icon":1},{"id":"2460073887","title":"Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think","url":"https://stock-news.laohu8.com/highlight/detail?id=2460073887","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460073887?lang=en_us&edition=fundamental","pubTime":"2024-08-17 22:01","pubTimestamp":1723903269,"startTime":"0","endTime":"0","summary":"Investors appear disappointed with Neurogene Inc.'s  recent earnings, despite the decent statutory profit number. We think that they may be worried about something else, so we did some analysis and found that investors have noticed some soft numbers underlying the profit.NasdaqGM:NGNE Earnings and Revenue History August 17th 2024. As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow  matches its profit. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.The fact that the company had unusual items boosting profit by US$16m, in the last year, probably goes some way to explain why its accrual ratio was so weak. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogenes-nasdaq-ngne-earnings-might-140109144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","NGNE","NDAQ"],"gpt_icon":0},{"id":"2458798639","title":"Neurogene’s NGN-401 Wins Key FDA Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2458798639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458798639?lang=en_us&edition=fundamental","pubTime":"2024-08-12 21:43","pubTimestamp":1723470198,"startTime":"0","endTime":"0","summary":"Neurogene (NGNE) has released an update. Neurogene Inc. has received RMAT designation from the FDA for their investigational gene therapy NGN-401, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogenes-ngn-401-wins-key-fda-designation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogenes-ngn-401-wins-key-fda-designation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2458986377","title":"Neurogene’s NGN-401 Shows Promise for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2458986377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458986377?lang=en_us&edition=fundamental","pubTime":"2024-08-12 21:43","pubTimestamp":1723470187,"startTime":"0","endTime":"0","summary":"Neurogene (NGNE) has released an update. Neurogene Inc. has achieved significant regulatory milestones with its NGN-401 gene therapy for Rett syndr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogenes-ngn-401-shows-promise-for-rett-syndrome?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogenes-ngn-401-shows-promise-for-rett-syndrome?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2458159452","title":"Neurogene Inc reports results for the quarter ended in June - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2458159452","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458159452?lang=en_us&edition=fundamental","pubTime":"2024-08-09 22:27","pubTimestamp":1723213628,"startTime":"0","endTime":"0","summary":"* Neurogene Inc    reported a quarterly adjusted loss of $1.09 per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of -80 cents.  The mean exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neurogene Inc reports results for the quarter ended in June - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2458569241","title":"Neurogene Q2 2024 GAAP EPS $(1.09) Misses $(1.06) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2458569241","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458569241?lang=en_us&edition=fundamental","pubTime":"2024-08-09 19:35","pubTimestamp":1723203345,"startTime":"0","endTime":"0","summary":"Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(1.06) by 2.83 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40281217/neurogene-q2-2024-gaap-eps-1-09-misses-1-06-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neurogene Q2 2024 GAAP EPS $(1.09) Misses $(1.06) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2458561560","title":"Neurogene Inc: Continues to Expect Current Cash, Cash Equivalents & Marketable Securities to Fund Operations Into H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2458561560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458561560?lang=en_us&edition=fundamental","pubTime":"2024-08-09 19:30","pubTimestamp":1723203001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240809:nTUAH8QMG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2458551561","title":"Neurogene Inc: Qtrly Shr Loss $1.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2458551561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458551561?lang=en_us&edition=fundamental","pubTime":"2024-08-09 19:30","pubTimestamp":1723203001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240809:nTUAH8QMG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2458569239","title":"Neurogene Q2 Operating Expenses USD 21.059 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2458569239","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458569239?lang=en_us&edition=fundamental","pubTime":"2024-08-09 19:30","pubTimestamp":1723203000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240809:nPLX89E9BC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","USD","NGNE"],"gpt_icon":0},{"id":"2458569684","title":"Press Release: Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2458569684","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458569684?lang=en_us&edition=fundamental","pubTime":"2024-08-09 19:30","pubTimestamp":1723203000,"startTime":"0","endTime":"0","summary":"NGN-401 gene therapy for Rett syndrome received RMAT designation from FDA based on preliminary clinical evidence indicating the potential to address unmet medical needs. NGN-401 selected for FDA START Program, also designed to accelerate development. Interim NGN-401 efficacy data from Cohort 1 remains on track for 4Q:24. Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates.Phase 1/2 Trial of NGN-401 Gene Therapy for Treatment of Rett Syndrome. June that high-dose NGN-401 was well-tolerated with an early favorable","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2457081775","title":"Neurogene’s NGN-401 Granted RMAT Status for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2457081775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457081775?lang=en_us&edition=fundamental","pubTime":"2024-08-07 19:57","pubTimestamp":1723031860,"startTime":"0","endTime":"0","summary":"Neurogene (NGNE) has provided an update. Neurogene Inc. has recently announced that the FDA awarded its gene therapy drug, NGN-401, the coveted RMA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogenes-ngn-401-granted-rmat-status-for-rett-syndrome?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogenes-ngn-401-granted-rmat-status-for-rett-syndrome?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2457817504","title":"Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2457817504","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457817504?lang=en_us&edition=fundamental","pubTime":"2024-08-07 19:30","pubTimestamp":1723030200,"startTime":"0","endTime":"0","summary":"Designation based on preliminary clinical evidence from ongoing NGN-401 clinical trial that shows potential to address unmet medical needs in Rett syndrome. RMAT designation provides an opportunity for an Accelerated Approval pathway under the 21st Century Cures Act, and is in addition to NGN-401’s selection by the FDA for the START Pilot Program. NEW YORK, August 07, 2024----Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that NGN-401 received Regenerative Medicine Advanced Therapy  designation from the U.S. Food and Drug Administration  for the treatment of Rett syndrome. The designation was based on preliminary clinical evidence from the ongoing Phase 1/2 clinical trial with NGN-401 that shows potential to address unmet medical needs in this disease.NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6FiM3Pk.g5_x3_D0Ib_TKg--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f24e822d964eaea47c5a736f1c965099","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6FiM3Pk.g5_x3_D0Ib_TKg--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f24e822d964eaea47c5a736f1c965099"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-announces-rmat-designation-ngn-113000528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NGNE","UK","BK4205","BK4528","BK4233"],"gpt_icon":0},{"id":"2457589658","title":"Neurogene Inc    expected to post a loss of $1.05 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2457589658","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457589658?lang=en_us&edition=fundamental","pubTime":"2024-08-07 10:55","pubTimestamp":1722999342,"startTime":"0","endTime":"0","summary":"* Neurogene Inc     is expected to report resultson August 8 (estimated) for the period ending June 30 2024   *    * LSEG's mean analyst estimate for Neurogene Inc is for a loss of $1.05 per share.   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neurogene Inc    expected to post a loss of $1.05 a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2454360645","title":"Leerink Partners Sticks to Its Buy Rating for Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2454360645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2454360645?lang=en_us&edition=fundamental","pubTime":"2024-07-26 13:59","pubTimestamp":1721973589,"startTime":"0","endTime":"0","summary":"In a report released on July 24, Mani Foroohar from Leerink Partners maintained a Buy rating on Neurogene (NGNE – Research Report). The company’s s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-neurogene-ngne?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-neurogene-ngne?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE"],"gpt_icon":0},{"id":"2448829153","title":"Neurogene to Participate in BMO Genetic Medicines Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2448829153","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2448829153?lang=en_us&edition=fundamental","pubTime":"2024-07-02 19:30","pubTimestamp":1719919800,"startTime":"0","endTime":"0","summary":"NEW YORK, July 02, 2024----Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the BMO 2024 Genetic Medicines Summit.\" and participate in investor meetingsDate: Tuesday, July 9 at 8:30 a.m. ET","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EcSRay.K_kOvXgriHJVeAg--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/70d9511abf53bcbe9528fc1672b7f0c5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EcSRay.K_kOvXgriHJVeAg--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/70d9511abf53bcbe9528fc1672b7f0c5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-participate-bmo-genetic-medicines-113000820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMO","NGNE","BK4207","BK4121","BK4139","GENE","BK4211","SMMF","MDCO"],"gpt_icon":0},{"id":"2448999017","title":"Neurogene to join Russell 3000 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2448999017","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2448999017?lang=en_us&edition=fundamental","pubTime":"2024-07-01 19:45","pubTimestamp":1719834321,"startTime":"0","endTime":"0","summary":"Neurogene (NASDAQ:NGNE) said it will be added to the Russell 3000 Index, effective at the open of U.S. equity markets on July 1.\nPress Release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4120958-neurogene-to-join-russell-3000-index","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["TQQQ","QID","SQQQ","QLD","QQQ","BK4139","NQmain","PSQ",".IXIC","MNQmain","NGNE"],"gpt_icon":0},{"id":"2448459991","title":"Neurogene Announces Addition to Russell 3000® Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2448459991","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2448459991?lang=en_us&edition=fundamental","pubTime":"2024-07-01 19:30","pubTimestamp":1719833400,"startTime":"0","endTime":"0","summary":"NEW YORK, July 01, 2024----Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Neurogene will be added to the Russell 3000 Index, effective at the open of U.S. equity markets today, Monday, July 1, 2024.The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30, 2024, ranking them by total market capitalization. Neurogene’s membership in the U.S. all-cap Russell 3000 Index will remain in place for one year. Neurogene has also been added to the Russell 2000 Index and the Russell Microcap Index.Statements in this press release that are not historical in nature are intended to be, and hereby are identified as, forward-looking statem","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g8yCkv3uF.Bf40Qa9wNLWQ--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/14d869e1d7ef2e56e2f0ec7b7a4a1683","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g8yCkv3uF.Bf40Qa9wNLWQ--~B/aD00ODA7dz0zNzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/14d869e1d7ef2e56e2f0ec7b7a4a1683"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurogene-announces-addition-russell-3000-113000951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2446438536","title":"BMO Initiates Neurogene at Outperform With $65 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2446438536","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446438536?lang=en_us&edition=fundamental","pubTime":"2024-06-27 19:57","pubTimestamp":1719489454,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4139","NGNE","IQ","MT","BK4561","BK4006","BMO","BK4207"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurogene.com","stockEarnings":[{"period":"1week","weight":-0.1108},{"period":"1month","weight":0.1536},{"period":"3month","weight":0.079},{"period":"6month","weight":0.6145},{"period":"1year","weight":2.5566},{"period":"ytd","weight":1.4959}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":0.0158},{"period":"3month","weight":0.0636},{"period":"6month","weight":0.1393},{"period":"1year","weight":0.4036},{"period":"ytd","weight":0.2182}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.087633},{"month":2,"riseRate":0.3,"avgChangeRate":-0.066901},{"month":3,"riseRate":0.5,"avgChangeRate":0.07464},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.109442},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.011201},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.067793},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.101505},{"month":8,"riseRate":0.909091,"avgChangeRate":0.860852},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.065613},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.057195},{"month":11,"riseRate":0.5,"avgChangeRate":0.080718},{"month":12,"riseRate":0.7,"avgChangeRate":0.189368}],"exchange":"NASDAQ","name":"NEUROGENE INC","nameEN":"NEUROGENE INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUROGENE INC,NGNE,NEUROGENE INC股票,NEUROGENE INC股票老虎,NEUROGENE INC股票老虎国际,NEUROGENE INC行情,NEUROGENE INC股票行情,NEUROGENE INC股价,NEUROGENE INC股市,NEUROGENE INC股票价格,NEUROGENE INC股票交易,NEUROGENE INC股票购买,NEUROGENE INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}